



## CANCER COUNCIL NSW

### New research project grants

L Bendall University of Sydney	The role of sphingosine-1-phosphate in haematopoietic stem cell egress from the bone marrow	\$120,000
T Byran University of Sydney	Recruitment of human telomerase to telomeres	\$120,000
A deFazio University of Sydney	Pathways of malignant progression in ovarian cancer	\$115,250
P Greer University of Newcastle	Real-time dose monitoring for patient safety in radiation therapy	\$120,000
M Kohonen-Corish Garvan Institute of Medical Research	Functional characterisation of the putative tumour suppressor gene MCC in colorectal cancer	\$120,000
T Liu University of New South Wales	Targeting Myc onco-protein degradation for the treatment of Myc-induced malignancies	\$106,500
G Lyons University of Sydney	Restoring epithelial differentiation to squamous cell carcinomas	\$120,000
M Baker Macquarie University	A Colorectal Cancer "Interactome" Paradigm that Influences Patient Survival	\$100,000
<b>Total new research project grants</b>		<b>\$921,750</b>

### 2010 Priority-driven Collaborative Cancer Research Scheme (grants co-funded with Cancer Australia)

B Meiser University of NSW	Too much, too soon? The impact of treatment-focused genetic testing in patients newly diagnosed with breast cancer	\$22,020
D Goldstein University of Sydney	LAP07: Randomised multicentre phase III study in patients with locally advanced adenocarcinoma of the pancreas: gemcitabine with or without chemoradiotherapy and with or without erlotinib	\$28,386
D Hart University of Queensland	RNA Loading of Tumor Associated Antigens and the Activation of Blood Dendritic Cells for Prostate Cancer Immunotherapy	\$32,601
A Haydon Monash University	SCOT - Short Course Oncology Therapy. A study of adjuvant chemotherapy in colorectal cancer	\$32,855
T Leong University of Sydney	Randomised phase II/III study of preoperative chemoradiotherapy versus chemotherapy for resectable gastric cancer	\$6,076
M Poulsen Princess Alexandra Hospital	Phase II efficacy study of chemo-radiotherapy in PET staged II-III merkel cell carcinoma of the skin	\$10,139
J Young University of Sydney	Quality of life outcomes and cost effectiveness of pelvic exenteration for people with advanced rectal cancer	\$21,101
<b>Total 2010 Priority-driven Collaborative Cancer Research Scheme</b>		<b>\$153,178</b>

### Continuing research project grants

L Ashman University of Newcastle	Tetraspanin proteins in prostate cancer progression and prognosis	\$113,000
M Bebawy University of Sydney	Microparticle-mediated transfer of P-glycoprotein in conferring multidrug resistance in cancer	\$119,375
J Byrne University of Sydney	The molecular basis of cell transformation produced by TPD52 overexpression	\$90,750
S Chen Westmead Hospital	Randomised trial of diagnostic strategies for invasive aspergillosis in at-risk haematology patients: Funding extension	\$67,875
R Daly Garvan Institute of Medical Research	Tyrosine kinase profiling of human basal breast cancers	\$115,250

# REPORTS

M Fabbro University of Sydney	Dynamin inhibitors as new anti-cancer drugs	\$114,500
D Gottlieb University of Sydney	Adoptive immunotherapy for the prevention of Varicella-zoster virus reactivation post stem cell transplant	\$95,750
N Haass Centenary Institute	The role of melanoma stem cells in melanomagenesis	\$116,000
C Jolly University of Sydney	Understanding AID-induced cancer: Unravelling complex mutation and repair pathways	\$116,000
K McDonald University of Sydney	The role of IQGAP1 in actively migrating glioma cells and its regulation by miR-124	\$110,750
M Murray University of Sydney	Development of personalised dosage protocols for tyrosine kinase inhibitors in oncology patients	\$95,550
M Naylor Garvan Institute of Medical Research	Role of beta1 integrin in prostate development and carcinogenesis	\$116,000
G O'Neill University of Sydney	The signalling switch function of the pro-metastatic, adhesion adaptor protein HEF1	\$116,000
S Tangye Garvan Institute of Medical Research	EBV-specific CD8+ Tcells in anti-tumour immune responses in patients predisposed to developing lymphoma	\$116,000
M Williams University of Wollongong	A dosimetric Inter-Comparison of Australian Radiotherapy IMRT Systems (ICARIS)	\$88,375
Zu Dong Zhang (Avery-Kiejda) University of Newcastle	Targeting p53 isoforms, p40p53 and p53β, to promote chemo-sensitivity in human melanoma	\$115,000
M Apte University of NSW	Desmoplasia in Pancreatic Cancer: Role of Pancreatic Stellate Cells in Cancer Progression	\$100,000
L Ashton University of NSW	Long-term health outcomes in survivors of childhood cancer and their families	\$100,000
M Baker Macquarie University	Lynchpin protein interactions that drive epithelial cancer malignancy	\$100,000
R Clifton-Bligh University of Sydney	Cross-talk between PPARγ and MAP kinase pathways in thyroid cancer	\$78,500
M Crossley University of Sydney	The role of zinc finger proteins in B cell cancer	\$100,000
D Damian University of Sydney	Nicotinamide protection from ultraviolet radiation-induced skin carcinogenesis in humans	\$100,000
M Friedlander University of NSW	Accelerated first line chemotherapy for advanced germ cell tumours	\$83,636
M Friedlander University of NSW	Intraperitoneal Chemotherapy with Paclitaxel and Cisplatin after Optimal Debulking Surgery for Ovarian Cancer	\$30,000
A Kneebone University of Newcastle	A phase III trial comparing adjuvant versus salvage radiotherapy for high risk patients post radical prostatectomy	\$49,000
F Mackay Garvan Institute of Medical Research	Role of neuropeptide Y1 receptor in regulatory T cell function - a new angle to treat autoimmunity and cancer	\$100,000
K MacKenzie University of NSW	Delineation of the role of telomeres and telomerase in erythropoiesis	\$97,425
J Rasko University of Sydney	Dissecting BORIS Function In Neoplasia	\$100,000
V Reeve University of Sydney	Protection against photoimmune suppression and skin cancer via oestrogen receptor signalling	\$100,000
N Suchowerska University of Sydney	Radiobiological Modelling for Intensity Modulated Radiation Therapy	\$70,000
A Swarbrick Garvan Institute of Medical Research	Defining the role for Id1 in breast cancer metastasis	\$56,375
L Trevena University of Sydney	A randomised trial of a web-based toolkit for applying evidence in the general practice cervical cancer prevention visit	\$73,500
N Verrills University of Newcastle	PP2A: a novel target for leukaemia therapy	\$100,000
<b>Total continuing research project grants</b>		<b>\$3,144,611</b>

## Continuing research program grants

# REPORTS

P Hogg University of NSW	New arsenical-based cancer drugs	\$375,618
M Norris University of NSW	Improved treatment outcomes for children with leukaemia	\$400,000
R Reddel Children's Medical Research Institute	Alternative lengthening of Telomeres: a target for cancer treatment	\$400,000
<b>Total research program grants</b>		<b>\$1,175,618</b>
<b>Strategic research partnership grants</b>		
A Biankin Garvan Institute of Medical Research	New South Wales Pancreatic Cancer Network	\$249,648
R Ward University of NSW	The Colorectal Cancer Research Consortium: A model for the integration of biomedical research into patient care	\$162,685
B Meiser University of NSW	Psychosocial impact of hereditary cancer and the development and evaluation of effective patient education and decision support strategies	\$129,796
J George University of Sydney	Epidemiology, prevention and management of liver cancer in NSW: Towards a strategic research partnership	\$250,000
L Palmer University of Western Australia	Clinical Outcomes and Genetic Epidemiology of high grade Glioma: COGEG	\$247,029
D Whiteman Queensland Institute of Medical Research	PROBE-NET : Progression of Barrett's Esophagus to Cancer Network	\$264,446
<b>Total strategic research partnership grants</b>		<b>\$1,303,604</b>
<b>New research program grant - in Pharmacogenomics</b>		
S Henshall Garvan Institute of Medical Research	Building capacity in pharmacogenomics across NSW: PRIME (Pharmacogenomic Research for Individualised Medicine)	\$300,000
<b>Total new program grants</b>		<b>\$300,000</b>
<b>International Cancer Genome Consortium (ICGC)</b>		
A Biankin Garvan Institute of Medical Research		\$500,000
<b>Total ICGC Grant</b>		<b>\$500,000</b>
<b>Other research programs</b>		
Cancer Trials NSW (CTN)		\$1,320,000
Cancer Epidemiology Research Unit (CERU) - Internal + External (Excluding NHMRC funding)		\$2,656,000
Centre for Health Research & Psycho-Oncology (CHeRP)		\$670,000
45 and Up Cohort Study		\$300,000
<b>Commissioned research projects</b>		
The Partners/carers study: A longitudinal study of the psychosocial outcomes of the partners/carers of cancer survivors		\$41,512
Action research for tackling tobacco in community based social services		\$27,540
Satisfaction survey evaluation of the Cancer Council Helpline and Call Back service		\$30,000
Multiple perspectives on sexuality and intimacy post-cancer, leading to the development and evaluation of supportive interventions		\$30,000
STREP Grants Stage 2 prioritisation processes		\$30,000
Nature and extent of sports sponsorship in children's sporting clubs and opportunities for policy intervention		\$34,000
Effects of food marketing on children and parents		\$25,000
Youthblock evaluation for Tackling Tobacco Program		\$30,000
Consumer research on front of pack food labelling		\$15,000
AHMRC 'Breathe' Project randomised trial		\$50,000
<b>Total other research programs and commissioned research</b>		<b>\$5,259,052</b>
<b>TOTAL RESEARCH FUNDED</b>		<b>\$12,757,813</b>